Application Note: MCP-1 protein has been tested by SDS-PAGE and is suitable as a control for polyclonal or monoclonal anti-MCP-1 in immunological assays.
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Other Performance Data: Biological Activity: MCP-1 activity is determined by the ability to chemoattract human monocytes or THP-1 cells at concentrations of 4 - 15 ng/mL. Endotoxin Level: Measured by kinetic LAL analysis and is typically ≤ 1 EU/μg protein.
Physical State: Lyophilized
Purity and Specificity: Purity was determined to be greater than 98% as determined by analysis by RP-HPLC and by reducing and non- reducing SDS-PAGE, against known standard.
Background: MCP-1, or Monocyte chemoattractant protein 1, of the intercrine beta (chemokine CC) family, is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. It augments monocyte anti-tumor activity and has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It may be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. MCP-1 exists as a monomer or homodimer; in equilibrium. It binds to CCR2 and CCR4 and is tethered on endothelial cells by glycosaminoglycan (GAG) side chains of proteoglycans. Processing at the N-terminus can regulate receptor and target cell selectivity. Deletion of the N-terminal residue converts it from an activator of basophil to an eosinophil chemoattractant. Recombinant Human MCP-1 produced in E. coli is a non-glycosylated, polypeptide chain containing 76 amino acids and having a molecular mass of 8607 Daltons.
Low Endotoxin: Yes
Other: User Optimized
English
Deutsch
